The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).
Silvia Marsoni
No relevant relationships to disclose
Andrea Bertotti
No relevant relationships to disclose
Andrea Sartore-Bianchi
Honoraria - Amgen; Bayer; Merck Serono
Francesco Leone
No relevant relationships to disclose
Sara Lonardi
No relevant relationships to disclose
Fortunato Ciardiello
No relevant relationships to disclose
Carmine Pinto
No relevant relationships to disclose
Massimo Aglietta
No relevant relationships to disclose
Vittorina Zagonel
No relevant relationships to disclose
Marcello Gambacorta
No relevant relationships to disclose
Walter Franco Grigioni
No relevant relationships to disclose
Massimo Rugge
No relevant relationships to disclose
Mauro Risio
No relevant relationships to disclose
Cosimo Martino
No relevant relationships to disclose
Emanuele Valtorta
No relevant relationships to disclose
Alberto Bardelli
No relevant relationships to disclose
Livio Trusolino
No relevant relationships to disclose
Paolo M. Comoglio
No relevant relationships to disclose
Salvatore Siena
No relevant relationships to disclose